Idogen AB (publ)
Idogen appoints Anders Karlsson as new CEO - Idogen
Nyemission: Idogen förbereder för fas I/IIa-studie Idogen är ett svenskt bioteknikbolag baserat i Lund. Bolaget utvecklar tolerogena cellterapier som gör det möjligt att undvika en oönskad aktivering av kroppens immunsystem. Cellterapin baseras
Idogen's IDO 8 granted orphan drug designation in the USA - Idogen
Idogen aktieägargrupp | Facebook
Stories: EIC-funded company Idogen starts trading on Nasdaq First North Growth Market | EIC Community
Idogen files patent application for new tolerogenic cell therapy
biotech | pharma | diagnostics | devices
Annual Report
Iodogen | C16H10Cl4N4O2 | ChemSpider
Board and Advisors | Ambulero
Idogen AB (publ) Org nr
niklas wallett - Idogen
Idogen will be listed on Nasdaq First North Growth Market on June 4, 2020
Idogen's Historical Milestones - Idogen
Trading Direkt analyserar bolagen på Spotlight 2018-10-18: Plejd & Idogen - YouTube
Idogen Year end report 3 - Idogen
Stories: EIC-funded company Idogen starts trading on Nasdaq First North Growth Market | EIC Community
BioInsights - Bringing advanced therapies to the clinic: the Swedish National ATMP Consortium (CAMP/SWElife ATMP)
biotech | pharma | diagnostics | devices
Idogen - Crunchbase Company Profile & Funding
